Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

320.56 -3.80 (-1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,242,480
Open 324.70
Bid (Size) 319.00 (1)
Ask (Size) 321.64 (14)
Prev. Close 324.36
Today's Range 319.00 - 326.97
52wk Range 249.70 - 346.85
Shares Outstanding N/A
Dividend Yield 2.66%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
Despite Medicare Negotiations, Americans May Still Have To Pay More For Prescription Drugs
Despite Medicare's first-ever negotiated drug prices under the Inflation Reduction Act, U.S. costs remain significantly higher than those in other wealthy nations, with some prices still more than... 
Via Benzinga
Topics Economy
Exposures Interest Rates

Performance

YTD
+7.79%
+7.79%
1 Month
-1.27%
-1.27%
3 Month
+5.20%
+5.20%
6 Month
+16.41%
+16.41%
1 Year
+23.56%
+23.56%

More News

Read More
(AMGN) - Analyzing Amgen's Short Interest
Via Benzinga
Amgen Unusual Options Activity For August 29
Via Benzinga
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
Via Investor's Business Daily
Smart Money Is Betting Big In AMGN Options
Via Benzinga
Amgen Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
Patchy But Still Bullish
Via Talk Markets
Intuit, Amgen And Sprott Uranium Miners ETF: CNBC's 'Final Trades'
Via Benzinga
Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug
Via Investor's Business Daily
Eli Lilly’s Path to the Next Trillion Market Capitalization
Via MarketBeat
3 Unstoppable Dividend Stocks to Buy Right Now
Via The Motley Fool
US Stocks May Take a Breather After S&P 500's Impressive 8-Session Winning Streak: Strategist Says Market Will Hit Fresh Highs In Next 4 Weeks, But Warns Investors Of Potential Risks
Via Benzinga
Topics Stocks
Exposures US Equities
ProInvestor Insights - August 2024
Via Talk Markets
2 Dow Jones Dividend Stocks With Above-Average Yields to Buy Now and Hold for at Least a Decade
Via The Motley Fool
Topics Stocks
Exposures US Equities
This Healthcare Giant Had 12 Products That Generated Double-Digit Growth Last Quarter and There's Still Many More in the Pipeline
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations
Via Investor's Business Daily
MarketBeat Week in Review – 8/5 - 8/9
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
Via Investor's Business Daily
The Defensive Sectors And VIX Have NOT Given The All-Clear Signal
Via Talk Markets
Topics Stocks
Exposures US Equities
Here's Why Eli Lilly Stock Dropped 12% Last Month
Via The Motley Fool
Amgen's Mixed Q2 Results Highlight Obesity Drug Potential, Analysts Focus Shifts To Upcoming Clinical Readouts
Via Benzinga
Why Amgen Stock Is Down Today Despite Solid Q2 Results
Via The Motley Fool
Wall Street Poised For Second Day Of Gains While Bank Of Japan Makes Reassurances; Dollar Strengthens Against Yen, Crude Prices Surge: What's Driving Markets Wednesday?
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.